Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orotic Acid SCHEMBL20865 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL29394966 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL422602 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL896844 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL7328854 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL23859825 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL16194628 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL231368 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL1005001 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL122311 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351834-B2 | Compositions and methods for the treatment of ornithine transcarbamylase deficiency | ARCTURUS THERAPEUTICS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4573193-A1 | GENE THERAPY FOR THE TREATMENT OF ARGININOSUCCINATE LYASE DEFICIENCY | UCL Business Ltd (GB) | 2025-06-25 | — | — | EP | disclosed |
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250136953-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2025-05-01 | — | — | US | disclosed |
| EP-3256218-B1 | A KDM1A INHIBITOR AND ITS USE IN THERAPY | IMAGO BIOSCIENCES INC (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118973577-A | Apostistin for the treatment of multiple system atrophy | 施万生物制药研发IP有限责任公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118340216-A | Medicinal and edible plant composition with uric acid reducing function and preparation method and application thereof | 湖南楚茗茶业有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118084819-A | Thiazole derivative and application thereof in treatment of leukemia | 华东师范大学 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024038287-A1 | GENE THERAPY FOR THE TREATMENT OF ARGININOSUCCINATE LYASE DEFICIENCY | UCL BUSINESS LTD (GB) | 2024-02-22 | — | — | WO | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-8017785-B2 | Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017785-B2 | Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2357174-A1 | Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357174-A1 | Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2123573-B1 | Control of volatile carbonyl compound in compositions used in printing | CELLRESIN TECH LLC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-1268217-B1 | CONTROL OF VOLATILE CARBONYL COMPOUND IN COMPOSITIONS USED IN PRINTING, PRINTING METHODS AND RESULTING PRINTED STRUCTURE | CELLRESIN TECH LLC (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20110053914-A1 | Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-7820769-B2 | Polymer for use in conduits, medical devices and biomedical surface modification | UCL BIOMEDICA PLC (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20080233164-A1 | Polymer for Use in Conduits, Medical Devices and Biomedical Surface Modification | UCL BIOMEDICAL PLC (GB) | 2008-09-25 | — | — | US | disclosed |
| WO-2007038524-A2 | COCRYSTALLIZATION METHODS | SSCI, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136953-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY | OTC, OAT, ODC1 | ALDH1A1 1644/4885LMNA 1834/4885CYP2C19 3247/4885 |
| US-12351834-B2 | Compositions and methods for the treatment of ornithine transcarbamylase deficiency | OTC, OAT, ODC1 | ALDH1A1 1644/4885LMNA 1834/4885CYP2C19 3247/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | ALDH1A1 734/4885LMNA 1600/4885CYP2C19 4564/4885 |
| US-20110053914-A1 | Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic | CACNA1A, GAP43, CACNG6 | ALDH1A1 514/4885LMNA 1500/4885CYP2C19 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.